Patents hurt drug innovation

So says the GAO. Apparently, drug development has not tracked very well to increases in development spending, especially for entirely new drugs. Pharmaceutical companies' ability to patent drugs which are very similar to existing drugs, but with minor or meaningless changes, has likely lessened their incentive to produce new and innovative drugs. The ACS Blog has more.